We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm (phno_amth)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01699607
First Posted: October 3, 2012
Last Update Posted: February 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Kelly Cosgrove, Yale University
Results First Submitted: July 14, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label)
Conditions: Nicotine Dependence
Healthy
Intervention: Drug: Amphetamine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cigarette Smokers Cigarette smokers are subjects who smoke 10 or more cigarettes per day for the past year. All subjects will receive amphetamine at 0.5 kg/mg to induce elevated dopamine levels in the brain. This dosage of amphetamine is given by mouth about 150 minutes prior to the second PET scan.
Nonsmoking Subjects Nonsmokers are subjects who have smoked less than 40 cigarettes in their lifetime, and none within the last year. All subjects will receive amphetamine at 0.5 kg/mg to induce elevated dopamine levels in the brain. This dosage of amphetamine is given by mouth about 150 minutes prior to the second PET scan.

Participant Flow:   Overall Study
    Cigarette Smokers   Nonsmoking Subjects
STARTED   6   4 
COMPLETED   6   4 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cigarette Smokers Cigarette smokers are subjects who smoke 10 or more cigarettes per day in the past year.
Nonsmoker Subjects Nonsmokers are subjects who smoked 40 cigarettes or less in their lifetime, and none within the past year.
Total Total of all reporting groups

Baseline Measures
   Cigarette Smokers   Nonsmoker Subjects   Total 
Overall Participants Analyzed 
[Units: Participants]
 6   4   10 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      6 100.0%      4 100.0%      10 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Gender 
[Units: Participants]
Count of Participants
     
Female      0   0.0%      1  25.0%      1  10.0% 
Male      6 100.0%      3  75.0%      9  90.0% 
Race/Ethnicity, Customized 
[Units: Participants]
     
Hispanic   1   1   2 
White, not of Hispanic origin   4   2   6 
African American   1   1   2 
Region of Enrollment 
[Units: Participants]
     
United States   6   4   10 


  Outcome Measures

1.  Primary:   Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.   [ Time Frame: first 90 minute scan at baseline, second 90 minute scan start 150 minutes post amphetamine administration ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Preliminary data. Small subject number.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Kelly Cosgrove, Ph.D.
Organization: Yale
phone: 203-737-6969
e-mail: kelly.cosgrove@yale.edu



Responsible Party: Kelly Cosgrove, Yale University
ClinicalTrials.gov Identifier: NCT01699607     History of Changes
Other Study ID Numbers: 0910005822
First Submitted: October 1, 2012
First Posted: October 3, 2012
Results First Submitted: July 14, 2015
Results First Posted: September 18, 2015
Last Update Posted: February 9, 2017